(CercleFinance.com) – The biopharmaceutical company Inventiva announces the selection of three scientific abstracts for poster presentation at the International Liver Congress 2022 organized by the Association for the Study of the Liver (EASL) from June 22 to 26 in London .
The first presentation demonstrates the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with NASH (non-alcoholic steatohepatitis) with non-cirrhotic fibrosis, independent of observed weight gain.
The other two illustrate the beneficial effect of treatment with lanifibranor on the FAST score and the identification of biomarkers of histological response in patients with non-cirrhotic NASH treated with lanifibranor.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
